AbCellera (NASDAQ: ABCL) is a Vancouver-based antibody discovery and development company that integrates biology, computation, and engineering to develop antibody-based medicines. Its technology platform combines high-throughput single-cell antibody screening, GPCR and ion-channel capabilities, bispecifics, antibody-drug conjugates…
immunology vancouver single-cell partnerships oncology biotech pharmaceuticals ion-channels gpcr apis-json antibody-drug-conjugates antibody-discovery monoclonal-antibodies bispecifics celium
-
Updated
Aug 14, 2026